Microfluidic chip systems for characterizing glucose-responsive insulin-secreting cells equipped with FailSafe kill-switch
This study establishes a proof-of-concept for the integration of a FailSafe kill-switch system into a glucose-responsive, insulin-secreting cell line to address the safety concerns in stem cell-derived cell replacement treatment for T1D. The microfluidic systems provided valuable insights into the functionality and safety of these engineered cells, demonstrating the potential of the kill-switch to reduce the risk of tumorigenicity in pluripotent cell-derived insulin-secreting cells.
Authors
- András Nagy (ORCID: https://orcid.org/0000-0003-4311-0413)
- Tatiana Oussenko
- Michael B. Wheeler (ORCID: https://orcid.org/0000-0002-7480-7267)
- Mohammad Izadifar (ORCID: https://orcid.org/0000-0001-5542-4335)
- Kacey J. Prentice (ORCID: https://orcid.org/0009-0003-9653-2828)
- Mira C. Puri (ORCID: https://orcid.org/0000-0003-0799-6122)
- Mohammad Massumi (ORCID: https://orcid.org/0000-0001-8291-9798)
- Biao Li (ORCID: https://orcid.org/0000-0002-0065-6304)
- Judith Elbaz
Institutions
- University Health Network (CA)
- University of Toronto (CA)
- Lunenfeld-Tanenbaum Research Institute (CA)
- Australian Regenerative Medicine Institute (AU)
- Toronto General Hospital (CA)
- Sinai Health System (CA)
- Monash University (AU)
Publication Details
- Journal
- Stem Cell Research & Therapy
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1186/s13287-024-04059-7
- Primary Topic
- Pancreatic function and diabetes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Canada Research Chairs
- Canadian Institutes of Health Research
- Banting and Best Diabetes Centre, University of Toronto